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REVIST A PORTUOUESA DE PNEUMOLOGIA 
cos e antihistaminicos carecem de bases fisiopato16gi-
casjustificativas, devendo ser abandonado. A vigilan-
cia das pneumopatias nas primeiras 24 a 48 horas de 
tratamento e apos a conclusao do mesmo, devera ser 
uma regra. Tam bern nesta fase se justifica a adopcao 
de criterios, de forma a seleccionar os doentes que 
realmente possam vir a beneficiar da realizacrao do Rx 
de t6rax de controle. Devera ter-se sempre em conta 
que a resolul):ao duma condensacrao pulmonar podera 
demorar ate 4 a 6 semanas, com as infeccroes virusais 
a serem as mais Jentas nas recuperacroes radiograficas. 
A brooquiolite, definida como "o primeiro 
epis6dio de tosse, pieira e hiperinsuflacrao em criancra 
com menos de do is anos de idade" , afecta pelo menos 
10% das criancyas no primeiro ano de vida, dos quais 
urn quinto necessitara de vigilancia ou internamento 
hospitalar. 
0 VSR e o principal agente etiol6gico, sendo 
responsavel por cerca de 75% dos casos. A subjacente 
necrose do epitelio dos pequenos bronquios, associada 
a inflarnacrao da mucosa e submucosa e a producrao de 
varios mediadores quimicos, todos contribuindo para 
a obstrucrao estruhtral e funcional dos pequenos 
bronqui.os, com consequente obstrucrao parcial (insu-
flacrao) ou total (atelectasia) dos aJveolos a jusante, 
justifica a potencial gravidade clfnica da bronquiolite. 
Nos tres primeiros dias de doencra, a progressiva 
gravidade do quadro clinico, justifica wna vigilancia 
apertada nos dois dias seguintes, se a criancra foi 
observada nos do is primeiros dias de doencra. Devera 
igualmente ter-se sempre em conta os factores de 
gravidadc - idade inferior a 3 meses, ex-premature 
( <34 semanas ), ocorrencia de apneias, cardiopatia 
congenita, displasia broncopulmonar, recusa alimen-
tar, letargia, SDR progressive com FR > 70 I min, Rx 
de t6rax com atelectasias - justificando a referencia 
hospitalar. 
Quality Issues in Respiratory Medicine 
WARREN H PERKS* 
Throughout Europe there is a demand to put into 
place systems which will reassure the public about 
monitoring and maintaining standards by our professi-
on. The process to ensure that standards are met is 
termed "clinical governance" (defined as the act af 
regulating proceedings clinically), which is und.arpin-
ned by lifelong learning (continual professional 
development - CPD) to provide doctors with the 
opportunities to update their skills and knowledge, as 
well as modernising and strengthening professional 
self-regulation. 
CPD is the acquisition of new skills and knowled-
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ge, both of a speciaUst and non-specialist nature. 
There are many aspects to CPO. Evidence-based 
medicine is the process where clinical management of 
the patient is based on high levels of evidence obtai-
ned by quality clinical trials. It is also recognised that 
the simple act of talking and communication with 
colleagues is probably the most important way of 
gaining knowledge. The reading of journals, textbo-
oks, following clinical guidelines, participating in 
grand-round, multidisciplinary meetings and teaching 
all contribute to the clinician's knowledge. Other 
learning resources include research, attendance at 
national scientific meetings, international meetings 
and sabbaticals. Finally, the pharmaceutical compani-
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cs can provide up-to-date (albeit sometimes biased) 
information on drug treatments. 
It is recognised that patient groups, insurance 
companies, medical managers and the Government, as 
purchasers of health care, wish for a high quality 
service. However, quality is difficult to define and 
assess. lt is no longer acceptable for the profession to 
act without providing quality measurements, although 
at the moment it is recognised that these arc not 
universally fair. 
Currently the best methods of measuring quality is 
monitoring continuous professional development by 
CME points, monitoring performance by medical 
audit, monitoring departments by peer review and 
monitoring the whole process where possible by 
quality indicators and outcome measures. There arc 
limitations to these crude tools. CME measures 
attendance at meetings and nothing more. Audit is 
time-consuming and often only measures easily 
measurable outcomes, it tends to be local and docs not 
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compare clinical activity from one hospital to another. 
The peer review system is very good for staffmg, 
resources, education and networking, but has a ten-
dency to be self-congratulatory. Quality indicators and 
outcome measures are currently at a rudimentary stage 
of development for medicine. 
lt is important that the medical profession ensures 
that it provides a quality and cost-effective service to 
its patients and society, before this role is undertaken 
by others (for example patient pressure groups, non-
-clinical managers and politicians). lt is vital that 
adequate infrastructures arc in place, eg staffing and 
funding. Nonetheless, the systems that are put into 
place should have the potential to detect team or 
individual problem areas at an early stage, to avoid 
sanctions or suspicions whlch undermine public 
confidence and threaten clinicians and their teams. 
Rectification of any problem rather than punishment 
should be the aim of clinical governance. 
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The UEMS advises the European Commissioners 
via the permanent committee of EU Doctors on 
training aspects within Europe. The mission state-
ment of the UEMS 1994 is that the doctors in training 
should, at the end of his/her training, have gained 
broad theoretical and scientific knowledge of respira-
tory diseese and all conditions affecting the lung, as 
well as having wider clinical experience. After 
training the doctor should be able to make indepen-
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dent decisions within all areas concerning respiratory 
disease and take care of both acute and non-acute 
patients. At the end of training the doctor should be 
able to audit and advise upon research projects 
relative to the speciality and to participate as a tutor 
and teacher in the field. 
The UEMS advocate harmonistation of training 
within the EU. Firstly, by virtue of European law, 
secondly because of the free movement of both 
patients and doctors within the EU, thirdly to promote 
shorter training, and finally to ensure quality training 
throughout Europe. 
The mean length of training within Europe i~ 12.6 
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